Hugel Inc (145020) - Net Assets
Based on the latest financial reports, Hugel Inc (145020) has net assets worth ₩980.16 Billion KRW (≈ $664.24 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.08 Trillion ≈ $729.76 Million USD) and total liabilities (₩96.68 Billion ≈ $65.52 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hugel Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩980.16 Billion |
| % of Total Assets | 91.02% |
| Annual Growth Rate | 30.32% |
| 5-Year Change | 26.13% |
| 10-Year Change | 287.72% |
| Growth Volatility | 91.01 |
Hugel Inc - Net Assets Trend (2014–2025)
This chart illustrates how Hugel Inc's net assets have evolved over time, based on quarterly financial data. Also explore 145020 current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Hugel Inc (2014–2025)
The table below shows the annual net assets of Hugel Inc from 2014 to 2025. For live valuation and market cap data, see market cap of Hugel Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩980.16 Billion ≈ $664.24 Million |
+16.57% |
| 2024-12-31 | ₩840.81 Billion ≈ $569.81 Million |
+7.84% |
| 2023-12-31 | ₩779.68 Billion ≈ $528.38 Million |
-1.57% |
| 2022-12-31 | ₩792.11 Billion ≈ $536.80 Million |
+1.93% |
| 2021-12-31 | ₩777.09 Billion ≈ $526.62 Million |
+4.07% |
| 2020-12-31 | ₩746.67 Billion ≈ $506.01 Million |
+6.74% |
| 2019-12-31 | ₩699.50 Billion ≈ $474.04 Million |
-3.88% |
| 2018-12-31 | ₩727.72 Billion ≈ $493.17 Million |
+4.60% |
| 2017-12-31 | ₩695.71 Billion ≈ $471.47 Million |
+175.20% |
| 2016-12-31 | ₩252.80 Billion ≈ $171.32 Million |
+21.63% |
| 2015-12-31 | ₩207.85 Billion ≈ $140.85 Million |
+290.60% |
| 2014-12-31 | ₩53.21 Billion ≈ $36.06 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hugel Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3834.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩1.16 Trillion | 122.06% |
| Total Equity | ₩950.26 Billion | 100.00% |
Hugel Inc Competitors by Market Cap
The table below lists competitors of Hugel Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hunan Corun New Energy Co Ltd
SHG:600478
|
$1.85 Billion |
|
Sanquan Food Co Ltd
SHE:002216
|
$1.85 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
$1.85 Billion |
|
Galapagos N.V.
AS:GLPG
|
$1.85 Billion |
|
Hubei Jianghan New Materials Co. Ltd. A
SHG:603281
|
$1.85 Billion |
|
UIE PLC
CO:UIE
|
$1.85 Billion |
|
Shenzhen Newway Photomask Making Co. Ltd. A
SHG:688401
|
$1.85 Billion |
|
Carabao Group Public Company Limited
BK:CBG-R
|
$1.85 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hugel Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 803,783,425,620 to 950,259,294,540, a change of 146,475,868,920 (18.2%).
- Net income of 140,871,770,930 contributed positively to equity growth.
- Share repurchases of 1,320,796,500 reduced equity.
- New share issuances of 5,956,399,810 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩140.87 Billion | +14.82% |
| Share Repurchases | ₩1.32 Billion | -0.14% |
| Share Issuances | ₩5.96 Billion | +0.63% |
| Other Changes | ₩968.49 Million | +0.1% |
| Total Change | ₩- | 18.22% |
Book Value vs Market Value Analysis
This analysis compares Hugel Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.87x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.78x to 2.87x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩25812.45 | ₩252500.00 | x |
| 2017-12-31 | ₩53891.35 | ₩252500.00 | x |
| 2018-12-31 | ₩57355.65 | ₩252500.00 | x |
| 2019-12-31 | ₩55844.92 | ₩252500.00 | x |
| 2020-12-31 | ₩59611.99 | ₩252500.00 | x |
| 2021-12-31 | ₩63859.89 | ₩252500.00 | x |
| 2022-12-31 | ₩67095.43 | ₩252500.00 | x |
| 2023-12-31 | ₩66640.00 | ₩252500.00 | x |
| 2024-12-31 | ₩73076.39 | ₩252500.00 | x |
| 2025-12-31 | ₩87976.45 | ₩252500.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hugel Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.82%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 33.14%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.13x
- Recent ROE (14.82%) is above the historical average (12.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 30.82% | 32.59% | 0.41x | 2.28x | ₩8.88 Billion |
| 2015 | 16.32% | 52.15% | 0.28x | 1.12x | ₩13.14 Billion |
| 2016 | 17.12% | 34.84% | 0.42x | 1.16x | ₩17.99 Billion |
| 2017 | 10.47% | 40.00% | 0.22x | 1.18x | ₩3.26 Billion |
| 2018 | 9.58% | 38.23% | 0.20x | 1.26x | ₩-3.04 Billion |
| 2019 | 6.38% | 21.81% | 0.23x | 1.28x | ₩-25.34 Billion |
| 2020 | 5.62% | 19.90% | 0.22x | 1.28x | ₩-32.68 Billion |
| 2021 | 7.43% | 23.55% | 0.24x | 1.30x | ₩-19.98 Billion |
| 2022 | 7.24% | 20.35% | 0.27x | 1.33x | ₩-21.88 Billion |
| 2023 | 12.45% | 29.11% | 0.34x | 1.24x | ₩18.35 Billion |
| 2024 | 16.90% | 36.41% | 0.40x | 1.17x | ₩55.44 Billion |
| 2025 | 14.82% | 33.14% | 0.39x | 1.13x | ₩45.85 Billion |
Industry Comparison
This section compares Hugel Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $210,358,050,483
- Average return on equity (ROE) among peers: 4.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hugel Inc (145020) | ₩980.16 Billion | 30.82% | 0.10x | $1.85 Billion |
| ORIENTBIO Inc. (002630) | $85.10 Billion | 15.13% | 0.14x | $43.15 Million |
| Green Cross (005250) | $221.73 Billion | 2.76% | 8.07x | $425.10 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $3.74 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $736.42 Million |
| GeneOne Life Science Inc (011000) | $26.74 Billion | 0.00% | 0.49x | $49.94 Million |
| HLB Co. Ltd (028300) | $46.46 Billion | 0.00% | 0.75x | $5.41 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $30.30 Billion | 5.14% | 0.15x | $19.29 Million |
| Seoulin Bioscience Co.Ltd (038070) | $53.72 Billion | 4.89% | 0.32x | $37.92 Million |
| Hyundai Bioscience Co. Ltd (048410) | $58.24 Billion | 3.27% | 0.77x | $872.13 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $77.34 Million |
About Hugel Inc
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more